CNBC·2026-02-07 20:46Core Viewpoint - Hims & Hers has decided to withdraw its copycat weight-loss pill from the market following controversy and potential legal threats from pharmaceutical giant Novo Nordisk and the FDA [1][2][4] Group 1: Company Actions - Hims & Hers announced the cessation of its compounded semaglutide pill after engaging in discussions with industry stakeholders [2] - The company had initially aimed to offer a cheaper version of Novo Nordisk's Wegovy weight-loss pill, priced at $49 for the first month, compared to Novo's price of approximately $100 more [2] - Hims & Hers maintains its commitment to providing safe and affordable care to millions of Americans [2] Group 2: Legal and Regulatory Context - Novo Nordisk threatened legal action against Hims & Hers, accusing the company of "illegal mass compounding" and deceptive advertising practices regarding GLP-1 products [3] - The FDA announced plans to take legal action against Hims & Hers, which includes restricting access to the ingredients used in the pill and referring the matter to the Department of Justice [4] Group 3: Marketing and Public Relations - Hims & Hers' announcement raises questions about its planned advertisement during Super Bowl 60, which features rapper Common discussing the health gap in America [4] - The company previously indicated that the advertisement is expected to provoke strong reactions [4]